ABSTRACT
Introduction: Remdesivir is an antiviral medication approved by the US Food and Drug Administration to combat COVID-19 infection in hospitalized patients. Although the adverse effects of Remdesivir are mainly unknown, data from randomized controlled trials have demonstrated its deleterious impact on several organ systems. Purpose: This study aims to describe the safety and efficacy of Remdesivir administration in a cohort of 586 patients admitted to a tertiary hospital in Qatar for COVID-19-related reasons. Methods: A retrospective study of 586 patients admitted with a diagnosis of COVID-19 and treated with Remdesivir were compared to 200 patients with COVID-19 who did not receive Remdesivir. Results: The rate of mechanical ventilation admission to the intensive care unit was comparable across the two groups (2.35% vs. 2%, p =.75). Death rates were comparable between the two groups (0.02% vs. 0.03%, p =.43). There was a mean reduction in heart rate within the first three days of antiviral therapy. Negligible variations in serum AST, ALT, ALP, and eGFR levels were detected. Remdesivir-treated patients had a significantly shorter hospital stay. Conclusion: Based on the limited data available regarding the adverse effects of Remdesivir, it is prudent to exercise caution by evaluating baseline parameters and avoiding concomitant use of potential cardio-, nephro-, or hepatotoxic drugs when using Remdesivir in patients hospitalized with COVID-19.